Clinical Research Directory
Browse clinical research sites, groups, and studies.
VITamin D and OmegA-3 TriaL (VITAL): Fractures, Vitamin D and Genetic Markers
Sponsor: Brigham and Women's Hospital
Summary
The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is a randomized clinical trial in 25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. This ancillary study is being conducted among participants in VITAL and will examine (1) whether vitamin D reduces incident total, non-vertebral fractures, and hip fractures and (2) whether this reduction is modified by vitamin D levels
Key Details
Gender
All
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
25871
Start Date
2018-06-01
Completion Date
2022-11-23
Last Updated
2026-04-27
Healthy Volunteers
Yes
Conditions
Interventions
Vitamin D3 placebo
Vitamin D placebo
Fish oil placebo
Fish oil placebo
omega-3 fatty acids (fish oil)
Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
Vitamin D3
Vitamin D3 (cholecalciferol), 2000 IU per day.
Locations (1)
Brigham and Women's Hospital
Boston, Massachusetts, United States